Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-23T19:59:39.109Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy and safety of topiramate in binge eating disorder: a systematic review and meta-analysis

Published online by Cambridge University Press:  09 July 2020

Mikail Nourredine ,
Lucie Jurek ,
Marine Auffret ,
Sylvain Iceta Open the ORCID record for Sylvain Iceta [Opens in a new window] ,
Guillaume Grenet ,
Behrouz Kassai ,
Michel Cucherat  and
Benjamin Rolland Open the ORCID record for Benjamin Rolland [Opens in a new window]
Mikail Nourredine*
Affiliation:
Department of Addictology, Centre Hospitalier Le Vinatier, Bron, France Department of Public Health, Hospices Civils de Lyon, Lyon, France
Lucie Jurek
Affiliation:
Department of Human Biology, Université Lyon 1, Lyon, France
Marine Auffret
Affiliation:
Department of Public Health, Hospices Civils de Lyon, Lyon, France
Sylvain Iceta
Affiliation:
Department of Endocrinology and nutrition, Hospices Civils de Lyon, Lyon, France Department of Nutrition, Laval university, Québec City, Québec, Canada
Guillaume Grenet
Affiliation:
Department of Public Health, Hospices Civils de Lyon, Lyon, France
Behrouz Kassai
Affiliation:
Department of Clinical Epidemiology, Hospices Civils de Lyon, Bron, France Department of Biostatistic, Université Lyon 1, Lyon, France
Michel Cucherat
Affiliation:
Department of Public Health, Hospices Civils de Lyon, Lyon, France Department of Biostatistic, Université Lyon 1, Lyon, France
Benjamin Rolland
Affiliation:
Department of Addictology, Centre Hospitalier Le Vinatier, Bron, France Centre de Recherche en Neurosciences de Lyon, Bron, France
*
Author for correspondence: Mikail Nourredine, Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

To assess the efficacy and safety of topiramate in treating binge eating disorder (BED), using a systematic review and meta-analysis of the available randomized clinical trials (RCTs).

Methods

The RCTs assessing topiramate vs placebo with or without adjunctive psychotherapy in BED were reviewed using a systematic search in the PubMed, Web of Science, PsycINFO, Cochrane Database of Systematic Review, and ClinicalTrials.gov search Websites, from inception to November 2019. Main outcomes were the changes in binge frequency, quality of life, and weight, respectively. Effect estimates were pooled using random-effect models and presented as risk ratios (RRs) or mean differences (MDs) and their 95% confidence interval (95% CI). Data extraction was performed by two independent reviewers.

Results

Three studies were eligible for inclusion, involving 528 BED patients. Topiramate was found to be significantly more efficacious than placebo in reducing: (a) the number of binge episodes per week (MD = −1.31; 95% CI = −2.58 to −0.03; I2 = 94%); (b) the number of binge days per week (MD = −0.98; 95% CI = −1.80 to −0.16; I2 = 94%); and (c) weight (MD = −4.91 kg; 95% CI = −6.42 to −3.41; I2 = 10%). However, participants in the topiramate groups withdrew significantly more frequently for safety reasons, relative to placebo participants (RR = 1.90; 95% CI = 1.13-3.18, I2 = 0%).

Conclusions

Preliminary findings support a possible efficacy of topiramate for the treatment of BED, even if safety concerns could limit the practical use of this treatment in BED subjects.

Keywords

Topiramatebinge eatingdisordermeta-analysissystematic review
Type
Review
Information
CNS Spectrums , Volume 26 , Issue 5 , October 2021 , pp. 459 - 467
Copyright
© The Author(s), 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Hudson, JI, Hiripi, E, Pope, HG, Kessler, RC. The prevalence and correlates of eating disorders in the national comorbidity survey replication. Biol Psychiatry. 2007;61(3):348–358.CrossRefGoogle ScholarPubMed
Heo, YA, Duggan, ST. Lisdexamfetamine: a review in binge eating disorder. CNS Drugs. 2017;31(11):1015–1022.CrossRefGoogle ScholarPubMed
Reas, DL, Grilo, CM. Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity. 2008;16(9):2024–2038.10.1038/oby.2008.333CrossRefGoogle ScholarPubMed
Johnson, B A, Ait-Daoud, N. Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des. 2010;16(19):2103–2112.CrossRefGoogle ScholarPubMed
McElroy, SL, Arnold, LM, Shapira, NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160(2):255–261.10.1176/appi.ajp.160.2.255CrossRefGoogle ScholarPubMed
McElroy, SL, Hudson, JI, Capece, JA, Beyers, K, Fisher, AC, Rosenthal, NR. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry. 2007;61(9):1039–1048.CrossRefGoogle ScholarPubMed
Brambilla, F, Samek, L, Company, M, Lovo, F, Cioni, L, Mellado, C. Multivariate therapeutic approach to binge-eating disorder: combined nutritional, psychological and pharmacological treatment. Int Clin Psychopharmacol. 2009;24(6):312–317.10.1097/YIC.0b013e32832ac828CrossRefGoogle ScholarPubMed
Appolinario, JC, Fontenelle, LF, Papelbaum, M, Bueno, JR, Coutinho, W. Topiramate use in obese patients with binge eating disorder: an open study. Can J Psychiatry. 2002;47(3):271–273.10.1177/070674370204700309CrossRefGoogle Scholar
McElroy, SL, Shapira, NA, Arnold, LM, et al. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry. 2004;65(11):1463–1469.10.4088/JCP.v65n1104CrossRefGoogle ScholarPubMed
Loring, DW, Williamson, DJ, Meador, KJ, Wiegand, F, Hulihan, J. Topiramate dose effects on cognition: a randomized double-blind study. Neurology. 2011;76(2):131–137.10.1212/WNL.0b013e318206ca02CrossRefGoogle ScholarPubMed
Brownley, KA, Berkman, ND, Peat, CM, et al. Binge-Eating Disorder in Adults: A Systematic Review and Meta-analysis. Ann Intern Med. 2016;165(6):409–420. doi:10.7326/M15-2455CrossRefGoogle Scholar
Moher, D, Liberati, A, Tetzlaff, J, Altman, DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7): e1000097.CrossRefGoogle ScholarPubMed
Higgins, JPT, Thompson, SG. Controlling the risk of spurious findings from meta-regression. Stat Med. 2004;23(11):1663–1682.10.1002/sim.1752CrossRefGoogle ScholarPubMed
Lau, J, Ioannidis, JPA, Terrin, N, Schmid, CH, Olkin, I. The case of the misleading funnel plot. BMJ. 2006;333(7568):597–600.CrossRefGoogle ScholarPubMed
Claudino, AM, De Oliveira, IR, Appolinario, JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry. 2007;68(9):1324–1332.10.4088/JCP.v68n0901CrossRefGoogle ScholarPubMed
Ghaderi, A, Odeberg, J, Gustafsson, S, et al. Psychological, pharmacological, and combined treatments for binge eating disorder: a systematic review and meta-analysis. Peer J. 2018;6:e511310.7717/peerj.5113CrossRefGoogle ScholarPubMed
Rubio, G, Martínez-Gras, I, Manzanares, J. Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence. J Clin Psychopharmacol. 2009;29(6):584–589.10.1097/JCP.0b013e3181bfdb79CrossRefGoogle ScholarPubMed
Hernández-Díaz, S, Smith, CR, Shen, A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78(21):1692–1699.10.1212/WNL.0b013e3182574f39CrossRefGoogle ScholarPubMed
Patorno, E, Bohn, RL, Wahl, PM, Avorn, J, Patrick, AR. Anticonvulsant medications and the risk of suicide. Attempted Suicide Violent Death. 2015;303(14):1401–1409.Google Scholar
Schuerch, M, Gasse, C, Robinson, NJ, et al. Impact of varying outcomes and definitions of suicidality on the associations of antiepileptic drugs and suicidality: comparisons from UK Clinical Practice Research Datalink (CPRD) and Danish national registries (DNR). Pharmacoepidemiol Drug Saf. 2016;25(Suppl 1):142–155.10.1002/pds.3928CrossRefGoogle Scholar
Symes, RJ, Etminan, M, Mikelberg, FS. Risk of angle-closure glaucoma with bupropion and topiramate. JAMA Ophthalmol. 2015;133(10):1187–1189.CrossRefGoogle ScholarPubMed
Dell’Orto, VG, Belotti, EA, Goeggel-Simonetti, B, et al. Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review. Br J Clin Pharmacol. 2014;77(6):958–964.10.1111/bcp.12283CrossRefGoogle ScholarPubMed
Ziad, EK, Rahi, AC, Abu Hamdan, S, Mikati, MA. Age, dose, and environmental temperature are risk factors for topiramate-related hyperthermia. Neurology. 2005;65(7):1139–1140.CrossRefGoogle Scholar
Karachristianou, S, Papamichalis, E, Sarantopoulos, A, Boura, P, Georgiadis, G. Hypohidrosis induced by topiramate in an adult patient. Epileptic Disord. 2013;15(2):203–206.Google Scholar
Tennis, P, Chan, KA, Curkendall, SM, et al. Topiramate use during pregnancy and major congenital malformations in multiple populations. Birth Defects Res A Clin Mol Teratol. 2015;103(4):269–275.CrossRefGoogle ScholarPubMed
Khan, A, Faught, E, Gilliam, F, Kuzniecky, R. Acute psychotic symptoms induced by topiramate. Seizure 1999;235–237.10.1053/seiz.1999.0287CrossRefGoogle Scholar
Zesiewicz, TA, Tullidge, A, Tidwell, J, Sullivan, KL, Hauser, RA. Topiramate-induced psychosis in patients with essential tremor: report of 2 cases. Clin Neuropharmacol. 2006;29(3):168–169.CrossRefGoogle ScholarPubMed
Karakilic, H, Hati, N, Karsliog, CE, Cos, ET. Topiramate-induced psychotic exacerbation: case report and review of literature. Int J Psychiatry Clin Pract. 2007;11(4):285–290.Google Scholar
Chen, LW, Chen, MY, Chen, K, Lin, H, Chien, C, Yin, H. Epilepsy & behavior topiramate-associated sexual dysfunction: a systematic review. Epilepsy Behav. 2017;73:10–17.CrossRefGoogle Scholar
Minozzi, S, Amato, L, Davoli, M, et al. Anticonvulsants for cocaine dependence (review). Heal San Fr. 2011;2011(10):3–6.Google Scholar
Singh, M, Keer, D, Klimas, J, Wood, E, Werb, D. Topiramate for cocaine dependence: a systematic review and meta-analysis of randomized controlled trials. Addiction. 2016;111(8):1337–1346.CrossRefGoogle ScholarPubMed
Pani, PP, Trogu, E, Pacini, M, et al. Anticonvulsants for alcohol dependence (review). Cochrane Database Syst Rev. 2014;2014(2):CD008544Google Scholar
Johnson, BA, Ait-Daoud, N, Bowden, CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361(9370):1677–1685.CrossRefGoogle ScholarPubMed
Johnson, BA, Ait-Daoud, N, Wang, X-Q, et al. Topiramate for the treatment of cocaine addiction. JAMA Psychiatry. 2013;70(12):1338CrossRefGoogle ScholarPubMed
Elkashef, A, Kahn, R, Yu, E, et al. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction. 2012;107(7):1297–1306.CrossRefGoogle ScholarPubMed
Anthenelli, RM, Heffner, JL, Wong, E, et al. A randomized trial evaluating whether topiramate aids smoking cessation and prevents alcohol relapse in recovering alcohol-dependent men. Alcohol Clin Exp Res. 2017;41(1):197–206.10.1111/acer.13279CrossRefGoogle ScholarPubMed
Kramer, CK, Leitão, CB, Pinto, LC, Canani, LH, Azevedo, MJ, Gross, JL. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes Rev. 2011;12(501):338–347.10.1111/j.1467-789X.2010.00846.xCrossRefGoogle ScholarPubMed
Johnson, BA, Rosenthal, N, Capece, JA, et al. Topiramate for treating alcohol dependence. JAMA. 2007;298(14):1641–1651.10.1001/jama.298.14.1641CrossRefGoogle ScholarPubMed
Jonas, DE, Amick, HR, Feltner, C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889–1900.10.1001/jama.2014.3628CrossRefGoogle ScholarPubMed
Zilberstein, B, Pajecki, D, De Brito, ACG, Gallafrio, ST, Eshkenazy, R, Andrade, CG. Topiramate after adjustable gastric banding in patients with binge eating and difficulty losing weight. Obes Surg. 2004;14(6):802–805.CrossRefGoogle ScholarPubMed
No Author. Don’t let Europe’s open-science dream drift. Nature. 2017;546(7659):451CrossRefGoogle Scholar